Ann DeWitt
COO @ The Engine
Boston, United States
Ann DeWitt is a seed investor at The Engine in Boston focused on Biotechnology and Health Care. Ann DeWitt is the General Partner of The Engine. She is a former COO at The Engine. She attended Harvard Business School, Massachusetts Institute of Technology, and University of Illinois Urbana-Champaign.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 46%
Last updated:
For AI agents: llms.txt
Industries Ann DeWitt invests in
Stages Ann DeWitt invests in
Countries Ann DeWitt invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (29%)
- Health Care 4 (17%)
- Medical 2 (8%)
- Big Data 2 (8%)
- Health Diagnostics 2 (8%)
Stage
- Seed 7 (29%)
- Series A 6 (25%)
- Series B 2 (8%)
- Pre-Seed 1 (4%)
- Series C 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $50M / Series C / Mar 26, 2026 | ||
| Bexorg is a techbio company that supports central nervous system drug discovery and development. The company uses its proprietary wet-lab platform, BrainEx, to generate human brain data. It trains predictive models and creates an AI engine to facilitate drug discovery research. | $23M / Series A / Oct 15, 2025 | ||
| Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages. | $23.4M / Series A / Oct 01, 2025 | ||
| Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $9M / Venture - Series Unknown / Apr 09, 2025 | ||
| Kano Therapeutics focuses on the correction of gene-length DNA using circular single-stranded DNA biomaterials. The company provides a comprehensive platform that combines manufacturing, application, and computational tools for genetic payload development. This approach empowers researchers and organizations to advance genetic cures effectively andsafely. | $5M / Seed / Aug 12, 2024 | ||
| Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages. | $5.2M / Seed / Jul 16, 2024 | ||
| Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $12M / Venture - Series Unknown / May 22, 2024 | ||
| Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $9M / Venture - Series Unknown / Sep 13, 2023 | ||
| Droplet Biosciences can offer earlier and more accurate cancer diagnosis by using lymphatic fluid. | $8M / Seed / Mar 16, 2023 | ||
| Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $10M / Series B / Jan 10, 2023 | ||
| See all 24 investments → | |||
Co-Investors
About The Engine
The Engine, which was publicly announced on October 26, 2016, was built by the Massachusetts Institute of Technology (MIT).Prioritizing breakthrough ideas over early profit, The Engine represents an exciting new system for startup support, one that shortens the time from idea to investment, and from investment to impact.To fuel The Engine,MIT is seeking to attract hundreds of millions of dollars of support and to provide hundreds of thousands of square feet of space for entrepreneurs in Kendall Square and nearby communities, starting with 26,000 square feet in its Central Square headquarters.The Engine provides a physical space where an idea can begin to take shape. It also streamlines the legal processes and agreements required to get products to market. And it links entrepreneurs to “patient capital” from investors who share their vision of addressing big challenges with big ideas.The Engine will eventually support up to 60 locally based startups concurrently; these companies will participate in the accelerator for up to 12 months. The Engine will make meaningful investments that will allow participating startups to get off the ground quickly and operate long enough to prove their concepts’ viability. It will also provide business planning, legal, and administrative support.The Engine will require less equity than is typical, allowing founders to maintain more control over their companies and the ideas they’ve created.Through the Engine Room, The Engine will provide access to a wide network of lab space, specialized equipment, business guidance, and other resources, at MIT and beyond.
The Engine Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Benjamin Downing
Vice President of Public Affairs
|
|||
Bettina Metais
VP Investor Relations and Operations
|
|||
Chloe Holzinger
Associate
|
|||
Dax Kepshire
Founder and Advisor
|
|||
Dulcie Madden
Partner and Head of Partnerships
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ann DeWitt invest in?
Ann DeWitt invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ann DeWitt?
Public channels for Ann DeWitt include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ann DeWitt last invest?
The most recent investment recorded for Ann DeWitt closed in Mar 2026. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
